Dapagliflozin is the first SGLT2 inhibitor shown to prevent type 2 diabetes in patients with heart failure and a reduced ejection fraction (HFrEF), according to a presentation at the ADA 2020 virtual scientific sessions . Endocrinologist Professor Silvio Inzucchi, from Yale School of Medicine, presented the latest update from the DAPA-HF study. The trial randomised ...
Preventing T2D: another string to the SGLT2i bow?
By Mardi Chapman
18 Jun 2020